Company profile

Mesoblast

Mesenchymal stromal cell therapeutics

MESO · NASDAQ · Australia / USA

Share price · MESO

$16.67+2.03 (+13.87%) 3M

close as of 2026-08-18 · 24h delayed · vol 182K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
remestemcel-L(Ryoncil (approved for pediatric SR-aGvHD))
Phase 3
Allogeneic MSC therapyCell therapy
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
Mesenchymal Precursor Cells (MPCs)No recent activity
Phase 2
Pancreatic islet cell replacementCell therapy
Heart Failure

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.